Bafna Pharmaceuticals Limited (BAFNAPH) - Total Assets
Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) holds total assets worth Rs1.61 Billion INR (≈ $17.38 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Bafna Pharmaceuticals Limited's book value for net asset value and shareholders' equity analysis.
Bafna Pharmaceuticals Limited - Total Assets Trend (2005–2025)
This chart illustrates how Bafna Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data.
Bafna Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Bafna Pharmaceuticals Limited's total assets of Rs1.61 Billion consist of 55.4% current assets and 44.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 2.2% |
| Accounts Receivable | Rs401.96 Million | 26.3% |
| Inventory | Rs280.86 Million | 18.4% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs0.00 | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Bafna Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Bafna Pharmaceuticals Limited worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bafna Pharmaceuticals Limited's current assets represent 55.4% of total assets in 2025, a decrease from 78.4% in 2005.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2025, down from 6.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 26.3% of total assets.
Bafna Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Bafna Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Bafna Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.67 | 1.96 | 2.24 |
| Quick Ratio | 1.03 | 1.24 | 1.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs322.50 Million | Rs366.10 Million | Rs217.67 Million |
Bafna Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Bafna Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.77 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | Rs1.53 Billion |
| Market Capitalization | $34.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bafna Pharmaceuticals Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bafna Pharmaceuticals Limited's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bafna Pharmaceuticals Limited (2005–2025)
The table below shows the annual total assets of Bafna Pharmaceuticals Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs1.53 Billion ≈ $16.55 Million |
+3.65% |
| 2024-03-31 | Rs1.48 Billion ≈ $15.97 Million |
+13.97% |
| 2023-03-31 | Rs1.30 Billion ≈ $14.01 Million |
+43.75% |
| 2022-03-31 | Rs901.45 Million ≈ $9.75 Million |
+4.25% |
| 2021-03-31 | Rs864.66 Million ≈ $9.35 Million |
+21.25% |
| 2020-03-31 | Rs713.13 Million ≈ $7.71 Million |
-40.31% |
| 2019-03-31 | Rs1.19 Billion ≈ $12.92 Million |
-13.65% |
| 2018-03-31 | Rs1.38 Billion ≈ $14.96 Million |
-22.40% |
| 2017-03-31 | Rs1.78 Billion ≈ $19.28 Million |
-7.38% |
| 2016-03-31 | Rs1.93 Billion ≈ $20.82 Million |
-3.66% |
| 2015-03-31 | Rs2.00 Billion ≈ $21.61 Million |
-15.26% |
| 2014-03-31 | Rs2.36 Billion ≈ $25.50 Million |
-9.50% |
| 2013-03-31 | Rs2.61 Billion ≈ $28.18 Million |
+19.02% |
| 2012-03-31 | Rs2.19 Billion ≈ $23.68 Million |
+61.43% |
| 2011-03-31 | Rs1.36 Billion ≈ $14.67 Million |
+61.21% |
| 2010-03-31 | Rs841.28 Million ≈ $9.10 Million |
+8.09% |
| 2009-03-31 | Rs778.29 Million ≈ $8.42 Million |
+52.23% |
| 2008-03-31 | Rs511.27 Million ≈ $5.53 Million |
-5.34% |
| 2007-03-31 | Rs540.09 Million ≈ $5.84 Million |
+151.65% |
| 2006-03-31 | Rs214.62 Million ≈ $2.32 Million |
+27.36% |
| 2005-03-31 | Rs168.51 Million ≈ $1.82 Million |
-- |
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more